Content Type: Article

  • The UPC Means Business: Latest Patentee Wins Preliminary Injunction

    The UPC Means Business: Latest Patentee Wins Preliminary Injunction

    ARTICLE / CLIENT ALERT

    The UPC Means Business: Latest Patentee Wins Preliminary Injunction

    September 25, 2023

    Read time: 3 min

    Key takeaways
    Overview

    The Unified Patent Court’s (UPC) Local Division Munich has granted a preliminary injunction in favor of 10x Genomics, preventing NanoString Technologies, Inc. from selling its CosMx Spatial Molecular Imager (SMI) instruments and CosMx reagents for RNA detection in 17 European Union countries.

    The decision was announced on September 20, 2023, after a two-day hearing held on September 5 and 6. This ruling confirms that the UPC is willing to take swift, decisive action in favor of plaintiffs, providing yet another win for patentees seeking to prevent alleged infringement. Notably, the Local Division Munich granted the preliminary injunction notwithstanding that the asserted claims had been amended from their original form as granted and signaled a willingness to consider further amended claims (i.e., auxiliary requests).

    This case is part of a broader campaign between 10x Genomics and NanoString Technologies that includes US litigation, German national litigation and European Patent Office (EPO) opposition proceedings. 10x Genomics previously obtained an injunction against the CosMx SMI instruments in a German national court. At the UPC, 10x Genomics brought infringement proceedings against NanoString Technologies and Vizgen, Inc. based on European Patent (EP) 4 108 782 B1, with stated case values of €10 million each. In response, NanoString Technologies filed for revocation of the patent on which the previous German injunction was based (EP 2 794 928 B1) and opposed EP 4 108 782 B1 at the EPO.

    While NanoString Technologies can appeal the decision, its stock price has reportedly dropped by 13% following the UPC’s ruling.

    In depth

    TEST

    Authors

    Diana Pisani

    European Patent Attorney

    London – 22 Bishopsgate

    More insights

  • HHS Proposes to Update Disability Nondiscrimination Regulations for First Time in Nearly 50 Years

    HHS Proposes to Update Disability Nondiscrimination Regulations for First Time in Nearly 50 Years

    ARTICLE / REPORT

    HHS Proposes to Update Disability Nondiscrimination Regulations for First Time in Nearly 50 Years

    September 22, 2023

    Read time: 2 min

    Overview

    Discrimination on the basis of disability has contributed to significant disparities in healthcare and child welfare. To address these disparities, the US Department of Health and Human Services (HHS) has proposed updated regulations implementing Section 504 of the Rehabilitation Act of 1973 to prohibit discrimination on the basis of disability in programs or activities that receive HHS funds. Although most of the revisions align with expectations imposed on stakeholders through other federal laws, some proposed changes are unique to HHS programs, including regulations impacting medical treatment, value assessments, medical diagnostic equipment, digital media and child welfare programs.

    In depth
    Tabs
    More insights
    Endnotes

  • Conseil d’Etat Delivers Long-Awaited Clarity on Regulation of Veterinary Clinics

    Conseil d’Etat Delivers Long-Awaited Clarity on Regulation of Veterinary Clinics

    ARTICLE / CLIENT ALERT

    Conseil d’Etat Delivers Long-Awaited Clarity on Regulation of Veterinary Clinics

    September 22, 2023

    Read time: 12 min

    Key takeaways
    Overview

    In a noteworthy (and long-awaited) set of case laws issued on July 10 2023, the Conseil d’Etat delivered four rulings on the shareholding and governance rules applicable to veterinary companies (Nos. 442911 and 452448), and on the terms and conditions under which veterinarian partners carry out their activities within such companies (“practising veterinarian partners”) (Nos. 448133 and 455961).

    In depth

    These rulings were issued in the context of divergent interpretations of the applicable regulations between, on the one hand, veterinarian clinic groups acting for market consolidation and, on the other hand, the veterinarian professional bodies (national and local veterinarian orders) concerning (i) the entry of non-professional investors (financial and industrial) into the capital of these veterinarian groups, (ii) the rules of governance of veterinary companies where non-professional investors are present and (iii) the organizational structure of groups of veterinary clinics, as a result of the consolidation trend seen in recent years, particularly with regard to the number of veterinarian partners and the number of professional practice sites.

    This opposition has led to numerous administrative and disciplinary proceedings initiated by the order of veterinarians, leading to several veterinary companies belonging to groups being removed from the register and disciplinary measures against the veterinarian partners of such groups.

    Although these four recent rulings all relate to veterinary companies governed by the provisions of the Rural and Maritime Fishing Code (RMFC) and the Service Directive 2006/123/EC of December 12 2006, the reasoning within the judgements passed by the Conseil d’Etat are also applicable to other regulated professions and, in particular, to healthcare professions (radiologists, ophthalmologists, dermatologists, etc.) for which regulations regarding shareholding, governance and prohibited shareholders are similar (see table below).

    Categories

    Veterinary

    Healthcare professions*

    Ownership structure and voting rights

    Ø For companies governed by Article L. 241 17 I 3° of the RMFC

     

    §  More than 50% of the share capital and the voting rights of the company must be owned, directly or through companies registered with the Order, by veterinarians practicing within the company.

    §  The remaining share capital and voting rights (up to 49.99 %) can be owned by non- practising veterinarians or any third party, including non-professionals.

     

    Ø For private practice companies (“société d’exercice liberal”), the same rules apply as for the health professions

    §  More than 75% of the capital and voting rights must be held by practising doctors (or more than 50% of the voting rights where more than 50% of the share capital are held by doctors not practising within the company – art. 5 of the law of December 31 1990 – art. 69 of Ordinance no. 2023-77).

     

    §  No more than 25% of the capital and voting rights may be held by third parties who are not doctors (art. 6 of the law of December 31 1990 – art. R. 4113-12 of the public health code).

    Corporate governance 

    §  The managers, the president, the president of the board of directors or the members of the executive board must legally practice the profession of veterinarian (art. L. 241-17 II 3° of the RMFC).

    §  The managers, the president, the president of the board of directors, the members of the management board, the president of the supervisory board and the managing directors, as well as at least two-thirds of the members of the board of directors or the supervisory board, must be active members of the company (art. 12 of the law of December 31 1990 – art. 58 to 62 of Ordinance no. 2023-77).

    Prohibited shareholders

    Ø A prohibition from holding directly or indirectly a participation within a veterinary company applies to any legal or natural persons who:

    §  in a professional capacity or in accordance with their corporate purpose engage in a professional activity of rearing, production or sale, free of charge or against payment, of animals or of transformation of products derived from animals; and

    §  legal or natural persons who do not practice as veterinarians and provide services, products or equipment used in the professional practice of veterinary medicine (art. L. 241-17 II 2° of the RMFC).

    A prohibition from holding directly or indirectly a participation within a doctor company applies to any legal or natural persons who practices:

    §  another medical or paramedical profession;

    §  the profession of pharmacist or veterinarian;

    §  the function of director/deputy director of a medical biology analysis laboratory;

    §  the activity of supplier, distributor or manufacturer of equipment related to the medical profession and of pharmaceutical products; or

    §  the activity of provider of services in the medical sector.

    * For doctors (radiologists, ophthalmologists, dermatologists etc.), with the exception of dental surgeons and pharmacists, for whom the acquisition of share capital and voting rights by non-professional third parties is prohibited.

    Four main observations arising from the Conseil d’Etat’s rulings of July 10 2023 concerning veterinary companies are likely to apply equally to healthcare professions.

    First observation

    The Conseil d’Etat has provided helpful clarification, both on the activities that qualify legal or natural persons as prohibited shareholders and on the types of holdings covered by the provisions on prohibited shareholders.

    After noting that the provisions of article L. 241-17 of the RMFC regarding prohibited shareholders must be interpreted and applied strictly, the Conseil d’Etat ruled that:

    • the ban of “direct or indirect” shareholdings in veterinary companies on certain people given the nature of their activities (subject to conflicts of interest) only applies to companies in the vertical chain of ownership above the practice company.

      The notion of prohibited shareholders therefore does not include the sister companies (a fortiori distant in the organizational chart) of the veterinary companies. In other words, the fact that a company holds subsidiaries carrying out prohibited activities does not prevent that company from acquiring an interest in a veterinary company. A shareholder may therefore hold shares in a veterinary company and in another entity carrying on a prohibited activity as long as the latter entity does not hold, directly or indirectly, shares in the veterinary company.

    • The provision by a non-professional shareholder of support services, in particular “management services, including accounting, financial, legal and administrative assistance, as well as marketing and price negotiation services […] cannot be regarded as “used in the course of the veterinary profession””, so that the provision of such services does not place a shareholder within the scope of prohibited shareholders (CE, 10 July 2023, Société Oncovet n° 452448).

    For Healthcare Professions

    The clarifications provided by the ConseiL d’Etat on the concept of prohibited activities and shareholders for veterinarians (based on the CRPM) are enlightening, and can no doubt be transposed to the healthcare professions, for which the Public Health Code provides for similar mechanisms. As with veterinarians, the provision of support services and administrative and financial assistance are not “related” to the exercise of professional activity within the meaning of the rules on prohibited shareholding.

    On the other hand, the interpretation that the notion of prohibited shareholders only covers companies in the vertical chain of ownership of the practice company obviously does not apply to medical biology laboratory companies, for which article L. 6223-5 of the Public Health Code expressly targets as prohibited shareholders persons holding stakes in companies carrying out certain prohibited activities.

    Second observation

    According to the Conseil d’Etat, the legal obligation on veterinarians “practicing within the company” to hold more than half of the capital and voting rights “means that they must effectively control the company”, thus guaranteeing “the independence of veterinarians with regard to any commercial imperatives that may be imposed on them” (CE, 10 July 2023, Anicura AB, n° 442911).

    It follows that the holding of an absolute majority of voting rights by the practising veterinarian partners amounts to a simple presumption of effective control, which may be rebutted in the presence of specific stipulations in the articles of association or any extra-statutory act which, in the context of an in concreto assessment, would render ineffective “the guarantees provided by the provisions of 1° of II of Article L. 241-17 of the French Rural and Maritime Fishing Code” (CE, 10 July 2023, Anicura AB, n° 442911).

    For Healthcare Professions

    The rule on the holding of more than 50 % of the voting rights of the company by professionals practicing within said company applies, under the same terms and conditions, to healthcare companies. It is therefore very likely that the Conseil d’Etat will also require that practising healthcare professionals hold the effective control of healthcare companies.

    Third Observation

    In order to rebut the simple presumption of “effective control” resulting from the holding of an absolute majority of voting rights by the veterinarian partners practicing within the company, the Conseil d’Etat uses the “group of evidence” approach to check that the statutory and extra-statutory provisions, taken as a whole, do not result in “the veterinarians, despite holding a majority of the capital and voting rights, not being in a position to effectively control the company”. (CE, July 10 2023, Société Oncovet n° 452448).

    In its rulings on July 10 2023, the Conseil d’Etat referred to the following evidence:

    • The qualified majority and quorum rules for shareholders’ meetings, which, given the distribution of share capital and voting rights, mean that no decision can be adopted without the approval of the non-professional shareholder[s]. The Conseil d’Etat gives the example of a two-thirds majority rule for the adoption of decisions at the shareholders’ meeting of a practice company in which 49.9% of the voting rights are held by [a] non-professional shareholder[s].
    • Voting agreements by which the practising veterinarian partners undertake in advance to vote in a manner determined by the non-professional shareholder[s], in particular regarding the entry or exclusion of professional shareholders or the distribution of dividends.
    • Unilateral undertakings to sell in which the veterinarian partners undertake to sell their shares to the non-professional shareholder[s], these promises being exercisable at any time by the non-professional shareholder[s], with the latter being responsible for designating the veterinarian[s] who will take their place on the date on which said undertakings are exercised.
    • The rules governing the composition, appointment and power of the company’s management bodies and committees. For the Conseil d’Etat, the existence of a supervisory committee of three members, two of whom are appointed by the investor[s] and responsible for approving draft resolutions prior to their submission to the general meeting, is an indication of the absence of effective control by the veterinarian partners. Therefore, to ensure the effective control by the practising veterinarian partners, the latter must appoint at least the majority of the members of the management bodies (strategy committee, supervisory board or others).

    For Healthcare Professions

    Given that healthcare private practice companies must also be subject to the effective control of the practising professionals, the Conseil d’Etat could follow the same analysis and use the group of evidence approach to ensure the effective control of a private practice company by the practising doctors partners.

    Fourth Observation

    Although mentioned in the list of evidence, any decoupling between the capital/voting rights and economic rights does not in itself appear to constitute an indication of the absence of effective control. On the other hand, allocating the majority (or even the essential part) of the economic rights to [a] non-professional shareholder[s] makes it all the more serious, in terms of its effects, that the practising shareholders do not have effective control over the company.

    In this respect, the Conseil d’Etat did not reconsider its own ruling on the decoupling between the capital/voting rights and economic rights, as set out in two rulings handed down on December 2 2019, one of which concerned a veterinary practice company (no. 410693).

    In this ruling the Conseil d’Etat considered that the existence of preferred shares granting to the non-professional shareholder a preferential financial right entitling the latter to receive most of the company’s profits complies with the ethical rules of the profession. To reach this conclusion, the Conseil d’État considered that the veterinarian shareholders still held the majority of the voting rights and therefore retained control over the decision as to whether or not to distribute dividends.

    The distribution of profits to a non-professional shareholder must therefore remain subject to the prior agreement of the veterinary shareholders, which ensures a reasonable balance of power and the independence of the latter.

    For Healthcare Professions

    The Conseil d’Etat has also acknowledged the ability to provide for the decoupling between ownership of capital/voting rights and economic rights for a private practice company operating a private medical biology laboratory (CE, December 2 2019, no. 404973).

    Three further observations are worth mentioning.

    Firstly, although not mentioned by the Conseil d’Etat in its rulings of July 10 2023, the requirement for the veterinary partners to have effective control over the company hinders the conclusion of a cash management agreement (or cash pooling) with the non-professional shareholder, insofar as Article L. 511-7 of the French Monetary and Financial Code provides that such agreements may only be entered into if there are “direct or indirect capital links between companies giving one of the associated undertakings effective control over the others”.

    Secondly, the Conseil d’Etat considered that practising veterinarian partners in a veterinary practice company must be “veterinarians who practise animal medicine and surgery within the company” (CE, July 10 2023, Société Univetis, no. 455961). On the contrary, the Conseil d’Etat has ruled that the mere fact that a veterinarian partner is involved in the management of a veterinary company is not in itself sufficient to consider him or her to be a “practising” veterinarian.

    This reasoning is in line with the provisions of the Ordinance no. 2023-77 of February 8 2023, which states that “the mere performance of acts of management does not confer the status of practising professional”, regardless of the sector of activity concerned.

    Thirdly, regarding the possibility for veterinary companies to have several places of practice, the Conseil d’Etat has ruled that although the regulations do not require at least one of the practising veterinarian partners to work full-time in each place of practice, it is nevertheless essential that “one of the partners works, at least part-time, in each of the places of practice” (CE, July 10 2023, Mon Véto, 448133).

    The Conseil d’Etat does not set a minimum duration or number of acts that would allow this obligation to be satisfied, nor does it specify the period over which compliance with this rule should be verified. In light of the reasons for adopting this solution, it would seem quite reasonable to assume that it requires, at least, a monthly presence of a professional partner for 20 or 30% of the opening time of each place of practice.

    Authors
    More insights

  • In Good Hands: Compilation of Publicly Available Information Can Still Be a Trade Secret

    In Good Hands: Compilation of Publicly Available Information Can Still Be a Trade Secret

    ARTICLE

    In Good Hands: Compilation of Publicly Available Information Can Still Be a Trade Secret

    Sep 21, 2023

    Read time: 4 min

    Key takeaways
    Overview

    The US Court of Appeals for the First Circuit affirmed a district court decision, finding that a compilation of customer-related information, even if publicly available, is a protectable trade secret. Allstate Insurance Co. v. Fougere, Case No. 22-1258 (1st Cir. Aug. 29, 2023) (Gelpi, Lynch, Thompson, JJ.)

    Allstate hired two agents—James Fougere and Sarah Brody-Isbill—to sell the company’s auto and casualty insurance products in Massachusetts. In connection with their employment, both agents signed exclusive employment agreements that imposed numerous responsibilities, including an obligation to maintain information identified by Allstate as confidential, an undertaking not to misuse or improperly disclose the information and a promise to return the information to Allstate when their agency relationships terminated. Allstate eventually terminated its agreement with the agents because of noncompliance with Allstate regulations and Massachusetts state law.

    After the agreements were terminated, Allstate believed the agents had retained confidential information belonging to Allstate and had been using it to solicit Allstate customers. Allstate ultimately learned that the agents had kept confidential Allstate spreadsheets that contained the names of thousands of Allstate customers, along with their renewal dates, premiums, types of insurance, Allstate policy numbers, driver’s license numbers, home addresses, phone numbers and email addresses.

    Allstate filed suit against the former agents, bringing claims under both Massachusetts law and the federal Defend Trade Secrets Act (DTSA). The agents brought counterclaims under Massachusetts law, alleging that Allstate failed to provide adequate notice before their terminations, misappropriated information that belonged to the agents and wrongfully interfered with the agents’ contractual relations by engaging in bad-faith business practices. On summary judgment, the district court found that the agents misappropriated Allstate’s trade secrets and dismissed the agents’ counterclaims. The agents appealed.

    The agents argued that the customer information was available from various publicly available sources and therefore did not constitute a trade secret. The First Circuit disagreed, explaining that the compilation of publicly available information could constitute trade secrets, particularly where attempts to duplicate that information would be “immensely difficult.” The Court also found that the factual record suggested that not all of the customer information was publicly available—and certainly not in the same compilation as it would be from Allstate.

    The agents also argued that the customer information had no economic value. In analyzing this argument, the First Circuit looked to the employment agreements between the former agents and Allstate, which specifically stated that the misuse of Allstate’s confidential information would cause “irreparable damages” to Allstate. The employment agreements also provided a mechanism for terminated agents to sell their “economic interest” back to Allstate. The Court also relied on its finding that this sort of information would be valuable to Allstate’s competitors in attempting to market policies to Allstate customers so that the competitor could offer lower pricing. Taken together, the Court found that the customer data had economic value.

    The agents next argued that Allstate had not sufficiently protected the customer information. The First Circuit, affirming the district court, found that Allstate had multiple protections in place. For instance, the employment agreements contained provisions about how the confidential information should be stored. Allstate also took steps such as requiring passwords, restricting access to keep the information safe and revoking access upon termination. The Court found that these acts were sufficient to protect the customer information.

    Ultimately, the First Circuit affirmed the district court’s decision.

    Practice Note: The public availability of information subject to a confidentiality obligation is not a viable defense for a trade secret claim when recreating the full document would be “immensely difficult.” Additionally, language about the value of confidential information found in employment contracts can be used to support a claim of economic harm in a breach of trade secret action.

    Authors

    Sarah J. Fischer

    Partner

    Boston

    More insights
    Endnotes

  • CFTC Crackdown: Three DeFi Platforms Face Enforcement Actions

    CFTC Crackdown: Three DeFi Platforms Face Enforcement Actions

    ARTICLE / CLIENT ALERT

    CFTC Crackdown: Three DeFi Platforms Face Enforcement Actions

    September 20, 2023

    Read time: 7 min

    Key takeaways
    Overview

    On September 7, 2023, the Commodity Futures Trading Commission (CFTC) simultaneously filed and settled charges against three decentralized finance (DeFi) platforms, signaling a significant step toward CFTC regulatory oversight in the DeFi space. The three DeFi platforms offered, or made available for trading, contracts based on various cryptocurrencies and digital assets, including swaps and other derivatives under the Commodity Exchange Act (CEA) and CFTC regulations.

    The CFTC’s enforcement actions targeted Opyn, Inc., ZeroEx, Inc. and Deridex, Inc., accusing each company of illegally offering financial products, including derivatives, to US persons without proper CFTC registration.[1] Many legal analysts contend that recent enforcement actions herald the end of DeFi activities in the United States.[2] While these assertions may be overblown, they are not without merit.[3] The US Department of the Treasury’s recent book “Illicit Finance Risk Assessment of Decentralized Finance” put decentralized operators on notice that the more centralized and concentrated control a defined group exerts over a protocol (even a protocol claiming to be decentralized), the greater the risk of being recognized as an “unincorporated association” and therefore a target for regulatory enforcement.[4]

    Some market participants perceive these regulatory moves as a targeted response to escalating apprehensions surrounding the risks of unregulated leveraged and margined retail commodity transactions in the swiftly advancing DeFi sector.[5] However, a considerable faction of the industry and regulators argue that rather than stifling the growth of DeFi, these enforcement actions may serve as a necessary impetus to cultivate more robust and transparent operational frameworks, thus fostering sustainable development in the sector.

    In depth

    OPYN, INC.: oSQTH AND REGULATORY COMPLIANCE

    Opyn, Inc. offered a digital asset derivatives token known as oSQTH through its Opyn Protocol.[6] The token’s value was tied to Opyn’s proprietary index, Squeeth, which “tracked the price of ether squared relative to USDC.”[7] Opyn allowed users to enter long and short oSQTH positions. The CFTC determined that oSQTH tokens represented swaps and leveraged retail commodity transactions, bringing their offering within the CFTC’s regulatory purview, and charged Opyn with failing to register as a Swap Execution Facility (SEF) and neglecting to limit retail access to eligible contract participants as is required for SEFs under the CEA.[8] Despite certain efforts to comply with the CEA’s requirements, “such as blocking users with U.S. internet protocol addresses” from accessing the Opyn Protocol, these efforts were not fully “sufficient to actually block U.S. users from accessing the Opyn Protocol,” pursuant to the CFTC’s position.[9] Opyn was also charged with engaging in activities that should have been exclusive to registered futures commission merchants (FCMs), including deploying the Opyn Protocol for leveraged transactions and failing to establish a customer identification program pursuant to Bank Secrecy Act (BSA) obligations.[10] Further, Opyn lacked the necessary preconditions “to implement KYC and anti-money laundering procedures” by not requiring users to provide identifying information when enrolling in the platform.[11] Opyn was ordered to pay a $250,000 civil monetary penalty.[12]

    DERIDEX, INC.: PERPETUAL CONTRACTS AND REGULATORY LAPSES

    Deridex, Inc. faced similar allegations concerning its Deridex Protocol. The Deridex Protocol used smart contracts to offer leveraged derivatives positions, which the CFTC alleged qualified as swaps as defined in the CEA (i.e., “perpetual contracts” without the delivery of a commodity), further underscoring the CFTC’s firmly held view that so-called perpetual contracts are swaps.[13] Deridex was also charged with operating as an unregistered SEF by facilitating swaps between multiple participants and engaging in activities exclusive to registered FCMs, such as soliciting users to deposit assets for leveraged retail commodity transactions.[14] Like Opyn, Deridex failed to implement a customer identification program and took no effective steps to exclude US users.[15] Deridex was ordered to pay a $100,000 civil monetary penalty.[16]

    ZEROEX, INC.: OX PROTOCOL AND REGULATORY IMPLICATIONS

    ZeroEx, Inc. was charged for its Ox Protocol and front-end application, Matcha, which allowed users to trade various digital assets, including leveraged tokens from third-party issuers.[17] The CFTC alleged that these leveraged tokens were retail commodity transactions “with customers who were not eligible contract participants or eligible commercial entities,” necessitating registration and compliance with CFTC regulations and the CEA.[18] ZeroEx, Inc. was ordered to pay a civil monetary penalty of $200,000.[19]

    DISSENTING OPINION AND REGULATORY CONCERNS

    Notably, a dissenting opinion from CFTC Commissioner Summer Mersinger accompanied these enforcement actions.[20] She raised concerns regarding the basis for imposing sanctions on DeFi protocols, emphasizing that the CFTC didn’t provide any “indication that customer funds [had] been misappropriated or that any market participants [had] been victimized by the DeFi protocols on which the Commission [had] unleashed its enforcement powers.”[21] Commissioner Mersinger also questioned whether enforcement actions were suitable for addressing the complex regulatory questions posed by DeFi protocols, suggesting that rulemaking and stakeholder engagement might provide a more comprehensive approach.[22] She emphasized the need to balance regulatory oversight with fostering responsible innovation and stakeholder engagement.[23]

    CONCLUSION

    The CFTC’s recent enforcement actions demonstrate its commitment to addressing regulatory challenges within the digital asset space, particularly in response to the growing demand for regulatory intervention in the DeFi sector. The CFTC has remained steadfast in its position that when offering core derivative products based on digital assets to the public, whether in a centralized or decentralized manner, the laws and regulations must be followed.

    With the absence of comprehensive regulations specific to digital asset commodities, retail customers have been left vulnerable and without established safeguards that are present in traditional asset classes. The prevalence of information asymmetries within DeFi protocols, even in regulated markets, presents risks that must be mitigated to protect customers. These enforcement actions demonstrate a subtle yet significant challenge for DeFi platforms: striving to integrate the pioneering, decentralized nature of their technologies while also meeting the intricate and notably demanding compliance framework of US law. DeFi platforms’ promise of transparency and efficiency through blockchain technology may be compromised by operational designs that centralize certain functions “off-chain,” leading to a lack of transparency and regulatory clarity. The CFTC’s actions aim to strike a balance between innovation and protecting market participants while addressing the challenges posed by DeFi protocols.

    The recent stringent approach by the CFTC in enforcing regulations has sparked a discussion regarding the threat of the current trend for regulation through enforcement against the viability of DeFi in the US. To preserve the US crypto industry’s vibrancy (barring or perhaps in conjunction with more definitive legislation), fostering collaborative and practical regulations for DeFi businesses will be essential.

    We regularly advise clients on all types of NFTs, and how they should be treated under US law based on their characteristics, sales and distributions. Our FinTech & Blockchain team can help you navigate the ever-evolving legal landscape affecting your business, ensuring you remain up-to-date and compliant.

    Authors

    Rachel Rosen

    Partner

    New York – One Vanderbilt Avenue

    Ethan M. Heller

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • On the Stand with Justin Murphy

    On the Stand with Justin Murphy

    ARTICLE

    On the Stand with Justin Murphy

    September 18, 2023

    Read time: 4 min

    Key takeaways
    Overview

    A former federal prosecutor, Justin Murphy represents corporate and individual clients involved in government enforcement cases, including complex antitrust matters, fraud allegations and all phases of white-collar criminal and related civil proceedings.

    In this Q&A, Justin shares what he’s learned from being both a prosecutor and a defense lawyer, how he prepares his clients for trial, and why empathy and compassion always play a role in his strategy.

    In depth

    How far in advance do you start preparing a client for a trial?

    I start the moment I meet the client.

    I think it’s important to begin with the end in mind, and that includes developing a game plan and theme during the first meeting with a client in a new matter. Although most matters may not make it to trial, building a theme that’s consistent with the evidence in the case helps you stay organized and disciplined when presenting the key points. It also helps you focus your message so that it is easy to understand and relatable.

    What is one thing you took away from your time as a federal prosecutor?

    My time at the US Department of Justice (DOJ) was invaluable, especially the first-hand experience I gained leading investigations and developing cases. The knowledge about how cases are built on the government’s side is vital when I’m developing strategies for my client’s defense.

    What are some things every trial lawyer should know about being in a courtroom?

    You must know your case. Understanding the facts and your theme(s) gives you confidence in the courtroom and helps you stay calm during a trial’s high-stress moments.

    You need to have strong interpersonal skills and be civil. Acting civil doesn’t indicate a lack of passion for your client or their position. It means that you’re steering clear of unnecessary attacks that may frustrate a judge or jury.

    It’s also important to be versatile. I’m always willing to learn from others who may have more experience or different approaches—some (or all) of which may be quite effective.

    What is one thing about your practice that you want people to know?

    Besides my defense experience, I’ve been first chair of US and global investigations and prosecutions at the DOJ, which provided me valuable experience in high-stakes and crucial bet-the-company cases. As a recent example, I was trial counsel for the former CEO of DaVita in the landmark acquittal of the first-ever criminal “no-poach” market allocation case. This case was the first of its kind in the Antitrust Division’s efforts to prosecute certain labor market antitrust issues.

    What do you enjoy most about being a trial lawyer?

    I enjoy the focus, the authenticity, the energy and the perseverance required for the job. At the top of my list, however, is the empathy and compassion that I need to have for my clients.

    The stakes—including reputational risks—are high. Whether my client is an individual or a company, I’m in a special position to assist them during what is likely the worst time of their life. They’re in need of help more than ever, and need empathy, compassion and sometimes a little tough love to get them over the finish line.

    My clients don’t always know what they’re up against, and they need a lawyer who can direct and protect them. Everyone deserves a fair trial and an advocate, and I like being part of that process.


    Check out more trial lawyer interviews in our On the Stand series.

    Authors
    More insights

  • Design and Execution of a Cross-Border Deal

    Design and Execution of a Cross-Border Deal

    ARTICLE

    Design and Execution of a Cross-Border Deal

    September 15, 2023

    Read time: 2 min

    Key takeaways
    Overview

    Efficiently executing a cross-border transaction requires experience, pragmatism and a specialized skill set. We have closed transactions in more than 75 countries for buyers and sellers across the full spectrum of dealmaking, from venture capital and private equity to multinational corporations.

    This guide provides key considerations to evaluate and address when designing and implementing a successful cross-border transaction strategy.

     

    In depth
    Authors

    Andrew J. Warmus

    Partner

    Chicago

    Sam Snider

    Partner

    Atlanta

    Michael J. Bruno

    Partner

    Miami

    Fabrice Piollet

    Partner

    Paris

    More insights

  • Author or Algorithm: Recent Developments at the Intersection of Generative AI and Copyright Law

    Author or Algorithm: Recent Developments at the Intersection of Generative AI and Copyright Law

    ARTICLE / CLIENT ALERT

    Author or Algorithm: Recent Developments at the Intersection of Generative AI and Copyright Law

    September 14, 2023

    Read time: 8 min

    Key takeaways
    Overview

    The increasing sophistication of generative artificial intelligence (AI) has had widespread effects on fields ranging from art and film to law and healthcare. The implications for copyright law principles, such as authorship, infringement, and fair use, are significant, raising many complicated questions: Does the generative AI training or fine-tuning process infringe copyrights in other works? What is the proper scope of copyright protection for generative AI outputs? Who is liable for infringing works generated by AI? The copyright issues posed by generative AI are especially challenging because it is difficult to analogize generative AI models to precedent technology, policymakers have divergent definitions of what constitutes AI and many generative AI models are still evolving.

    In this On the Subject, we discuss recent developments relating to generative AI and copyright law. Specifically, we provide an overview of:

    • The US Copyright Review Board’s recent rejection of copyright protection for artwork created using generative AI.
    • The US District Court for the District of Columbia’s decision in Thaler v. Perlmutter,[1] affirming that human authorship is required for copyright registration.
    • The recent US Copyright Office initiative and request for comments to explore various hot topics regarding generative AI and copyright law.
    • The Copyright Office’s March 2023 policy statement providing registration guidance on works containing AI-generated material.
    In depth

    REJECTION OF COPYRIGHT PROTECTION FOR AI GENERATIVE ART

    The Copyright Office’s consistent position has been that AI-generated works are not entitled to copyright protection because they are not the product of human authorship. The Board applied this standard when it rejected copyright protection for an award-winning AI-generated artwork entitled “Théâtre d’Opéra Spatial.” Specifically, the Board held that the artwork contained “more than a de minimis amount of content generated by artificial intelligence,” which must be disclaimed to satisfy the human authorship requirement and qualify for copyright registration.

    Artist James M. Allen utilized the generative AI system “Midjourney,” a text-to-picture AI service, to create a science fiction-themed artwork, which made headlines when it won the 2022 Colorado State Fair art competition. Allen filed an application for copyright registration but did not disclose Midjourney’s role. In response to the Copyright Office’s request for additional authorship information, Allen stated that he (1) first input “numerous revisions and text prompts at least 624 times to arrive at the initial version of the image,” (2) used Adobe Photoshop to remove flaws and create new visual content and (3) used Gigapixel AI to “upscale” the image by increasing its resolution and size. The Copyright Office refused to register the work because Allen declined the examiner’s request to disclaim portions of the artwork generated by AI.

    Allen requested that the Copyright Office reconsider its initial refusal and register the entire artwork. The Copyright Office affirmed its rejection and concluded that although Allen’s human-authored edits made with Adobe Photoshop contained a sufficient amount of original authorship to be registered, the features generated by Midjourney and Gigapixel AI needed to be excluded/disclaimed as non-human authorship.

    Allen appealed to the Board, arguing that the Copyright Office ignored his creative input into Midjourney, placed “a value judgment on the utility of various tools” and overlooked the applicability of the fair use doctrine coming from his transformation of the AI-generated raw material. The Board affirmed the Copyright Office’s stance, holding that if a work containing AI-generated material also contains sufficient human authorship to support a claim to copyright, then the Copyright Office will register the human’s contributions.

    Applicants must disclose AI-generated content that is “more than de minimis” by including a brief description in the copyright registration application. The Board concluded that “Théâtre d’Opéra Spatial” contains an amount of AI-generated material that is more than de minimis and thus must be disclaimed because the Midjourney-generated image remains in substantial form in the final work and is not the product of human authorship. The same standard applies to Allen’s editing of the image via Gigapixel AI. According to the Board, inputting commands to a generative AI system does not amount to human authorship because the traditional elements of authorship are determined and executed by AI, not the human user.

    The Board noted there may be future cases where the application of the de minimis standard is a closer call; however, the significance of Midjourney’s influence in the final work is clearly apparent here. The Board concluded that Allen’s remaining arguments were unpersuasive.

    COPYRIGHT AUTHORSHIP OF AI-GENERATED WORKS

    A recent opinion from the DC District Court held that a valid copyright requires human—not machine—authorship. However, this rule’s application is not black and white because it largely depends on the amount of human control/contribution over the AI-generated output.

    The DC District’s decision in Thaler v. Perlmutter highlights the complexity of copyright authorship for AI-generated works. In 2018, Steven Thaler filed a copyright application to register an AI-generated visual art piece named “A Recent Entrance to Paradise.” The copyright application described the visual art as autonomously created by AI, identified the generative AI as the author and listed Thaler as the copyright claimant under the work-for-hire doctrine. The Board twice refused to register the work, finding that it lacked requisite human authorship because it was autonomously generated by AI. The Board also dismissed Thaler’s work-for-hire argument because AI cannot enter a binding legal contract. The DC District Court affirmed. The Copyright Act of 1976 provides immediate copyright protection to any work of authorship fixed in any tangible medium of expression. The DC District Court held that, although copyright law was designed to adapt to the times, there is an underlying and consistent understanding that human creativity is the driving force of copyrightability. AI is merely a tool used by humans.

    THE COPYRIGHT OFFICE’S NOTICE OF INQUIRY AND REQUEST FOR COMMENTS

    Authorship of AI-generated works underlies many of the critical issues raised in the Copyright Office’s August 2023 Notice of Inquiry and Request for Comments, which focuses on four categories of issues:

    1. The use of copyrighted works to train AI models
    2. The copyrightability of material generated using AI systems
    3. Potential liability for infringing works generated using AI systems
    4. Treatment of generative AI outputs that imitate the identity or style of human artists.

    Regarding the first issue, the prevailing question is whether using copyrighted works to train generative and non-generative AI is an infringing use. Because copyright infringement requires an act of actual copying, this fact-specific inquiry heavily depends on the type of AI. Additional facts such as the collection and curation of AI datasets, training material sources and retention of records may also affect this analysis and subsequent opinions/policy.

    Regarding the second issue, the uncertainty lies in where and how to draw the line between human creation and AI generation. The Copyright Office and US courts have repeatedly held that AI-generated work cannot be owned/authored by the AI itself because a valid copyright requires human authorship and creativity. However, the degree of human-authored contributions, or the level of control a human programmer has over the AI, may affect the copyrightability of the AI-generated work.

    The third issue rises and falls with authorship: Who is liable for AI-generated work that is substantially similar or identical to another copyrighted work? How should liability be apportioned between the user who inputted the prompt, the system developers, the AI tool’s corporate owner, etc.?

    Recent union strikes have highlighted the importance of the fourth issue: What protections, if any, do people have from AI copying their likeness? (Likeness includes image, voice and style.)

    The Copyright Office posed 34 questions regarding copyright law and generative AI for public comment. Instructions for submitting comments are available on its website. Interested parties are encouraged to respond and need not answer all the questions. The public comment period closes on October 18, 2023. These conversations bring the United States closer to finding policy solutions for the problematic copyright questions surrounding generative AI.

    NEXT STEPS

    For more information on this topic, advice on intellectual property considerations for AI-generated works, or assistance submitting comments on the Copyright Office’s notice of inquiry, please contact one of the authors below or your regular McDermott lawyer.

    Authors

    Sarah Bro

    Partner

    Orange County, Los Angeles

    Shawn C. Helms

    Partner

    Dallas

    More insights

  • Baker’s Dozen: Delaware Becomes 13th State to Enact State Consumer Privacy Law

    Baker’s Dozen: Delaware Becomes 13th State to Enact State Consumer Privacy Law

    ARTICLE / CLIENT ALERT

    Baker’s Dozen: Delaware Becomes 13th State to Enact State Consumer Privacy Law

    September 13, 2023

    Read time: 8 min

    Key takeaways
    Overview

    On September 11, 2023, Delaware Governor John Carney signed the Delaware Personal Data Privacy Act (DPDPA) into law, making Delaware the 13th state to enact a consumer privacy law. The DPDPA closely tracks the laws in Connecticut and Virginia, which is welcome news and a continuing sign that those state laws are serving as the model for other states. However, there are nuances in the DPDPA that make it a bit different, meaning businesses subject to the DPDPA will have to take certain steps to comply above and beyond existing or planned compliance activities. The DPDPA will go into effect January 1, 2025.

    Below, we provide an overview of some of the key aspects of Delaware’s new consumer privacy law.

    In depth

    WHO DOES DELAWARE’S PERSONAL DATA PRIVACY ACT (DPDPA) APPLY TO?

    Unlike the consumer privacy laws in California and Utah, the DPDPA does not include a revenue threshold. To be subject to the DPDPA, a business must do business in Delaware or target products or services to Delaware consumers, and either…

    • control or process personal data of 35,000 or more Delaware consumers (excluding data controlled or processed solely for the purpose of completing a payment transaction), or
    • control or process personal data of 10,000 or more Delaware consumers and derive more than 20% of gross revenue from the sale of that data.

    These thresholds are significantly lower than other states with consumer privacy laws, meaning more companies will be subject to the DPDPA than would be in other states under other consumer privacy laws.

    WHO IS A “CONSUMER”?

    In the DPDPA, a consumer is a natural person who is a resident of Delaware acting in a personal context. This means that employees and business-to-business (B2B) contacts are expressly excluded from the definition of consumer.

    WHAT IS “PERSONAL DATA”?

    Personal data in Delaware’s bill is defined as “information that is linked or reasonably linkable to an identified or identifiable individual.” It excludes, however, de-identified data, aggregate data and publicly available data. The limitations for de-identified data and publicly available data closely track those of Virginia (e.g., de-identification requires a public commitment to keep data de-identified, and public data is both from government files as well as data that is generally available through mass media sources).

    Although not included in the definition of personal data, companies do not need to include pseudonymous data (under certain circumstances) when responding to consumer requests under the DPDPA.

    WHO CAN ENFORCE?

    The Delaware Department of Justice has exclusive enforcement authority, and there is an express provision disclaiming the creation of any private right of action. For the calendar year of 2025, the Department of Justice is required to provide companies with 60 days’ notice and a cure period prior to commencing any enforcement actions. Beginning January 1, 2026, the provision of a cure period is left to the discretion of the Delaware Department of Justice. If an enforcement action follows, violations of the DPDPA can be up to $10,500 per violation.

    WHO IS EXEMPT?

    The DPDPA’s exemptions mirror those of other state consumer privacy laws. For example, exemptions include personal information covered by laws such as the Health Insurance Portability and Accountability Act, the Children’s Online Privacy Protection Act, the Gramm-Leach-Bliley Act, the Family Educational Rights and Privacy Act, and a litany of other federal laws.

    In addition, the DPDPA does not apply to government entities or nonprofit organizations.

    The DPDPA also has broad use exemptions for certain use cases such as compliance with law, preventing fraud or injury to others, and defending legal claims.

    WHAT OBLIGATIONS ARE IMPOSED?

    The DPDPA imposes what are now standard obligations on data controllers under state consumer privacy laws. Specifically, controllers must:

    • Limit the purpose of processing personal data to that which is reasonably necessary and proportional
    • Take steps to implement reasonable safeguards for the personal data within their control
    • Refrain from discriminating against consumers for exercising their rights and from processing personal data in violation of federal laws that prohibit discrimination
    • Be transparent in their reasonably accessible, clear and meaningful privacy notice
    • Ensure contracts control relationships with their processors (note: the law itself details the minimum necessary provisions of these contracts)

    WHAT CONSUMER RIGHTS ARE CREATED BY THE DPDPA?

    Controllers must provide what is now a standard set of consumer rights to Delaware consumers:

    • Opt-out rights related to the sale of personal data, targeted marketing and profiling (automated decision-making that could have significant legal effects such as related to housing, drinking water, credit, etc.)
    • Deletion rights (with respect to the data provided by or about the consumer)
    • Access rights, including a right to confirm whether controller is processing any data at all and to obtain a list of the categories of third parties to which the controller has disclosed the consumer’s personal data
    • Correction rights
    • Appeal rights
    • Data portability rights (limited to data the consumer previously provided). Controllers are given the option to respond to a data portability request with a “representative summary” of the personal data held rather than the data itself.

    With the exception of the provision of a list of the categories of third parties to whom personal data has been disclosed, these rights should look familiar to most companies by now.

    SENSITIVE DATA

    Under the DPDPA, the definition of sensitive data is arguably broader than it is under other state consumer laws and includes: data revealing racial or ethnic origin, religious beliefs, mental or physical health condition or diagnosis (including pregnancy), sex life, sexual orientation, status as transgender or nonbinary, citizenship status or immigration status, genetic or biometric data, personal information of a known child (under the age of 13), and precise geolocation (within a radius of 1,750 feet).

    A controller may not process (including collection) sensitive data without obtaining the consumer’s consent (or their parent’s consent, in the case of a known child).

    RESPONSE TO CONSUMER INQUIRIES

    As has become standard in state consumer privacy laws, controllers must respond to a consumer personal data request within forty-five (45) days of receipt of the request, with a forty-five (45) day extension available. If a consumer appeals a decision of the controller to deny a consumer request, the appeal response must be delivered within sixty (60) days. If the appeal is denied, controllers must provide the consumer with a method for contacting the Delaware Department of Justice.

    DATA PROTECTION ASSESSMENTS

    Controllers will need to conduct document privacy assessments before they engage in certain processing activities, including:

    • Processing for targeted advertising
    • Sale of personal data
    • Processing of personal data for profiling if the profiling presents a reasonably foreseeable risk of legal, deceptive, discriminatory, financial, reputational or physical harms
    • Processing sensitive data

    The required assessment must analyze the benefits of the processing to the company, consumer and public while weighing the harms and potential mitigants. The DPDPA allows for the use of impact assessments done under other state laws to count toward the requirements of the DPDPA and does not require retroactive impact assessments for processing activities occurring prior to the effective date of the law. One unique aspect of the DPDPA, however, is that if the assessment is produced to the Delaware Department of Justice, in order to preserve privilege over the assessment, the document produced must be “conspicuously” marked as privileged.

    WHEN DOES THE DPDPA TAKE EFFECT?

    The DPDPA comes into effect on January 1, 2025.

    ***

    Creating a successful, effective and comprehensive privacy program for your organization requires a thorough understanding of both the relevant legal obligations and the personal data subject to compliance. Setting up a program that is prepared to respond to various state privacy laws as they come into effect will save organizations time in the long run, especially as many of these laws reflect one another.

    If you have questions or need assistance in readiness work for the new state consumer laws, please contact your regular McDermott lawyer or reach out to David Saunders.

    Check out our additional coverage on new state consumer privacy laws: 

    California Reveals Draft Regulations Requiring Onerous Cybersecurity Audits and Privacy Risk Assessments

    State Regulators Step Up Enforcement of New Privacy Laws

    Ruling Delays Enforcement of Latest CCPA Regulations

    Oregon Joins the Consumer Privacy Trend

    Texas Consumer Privacy Law Nears Governor’s Signature

    Florida Adds a New Twist to Consumer Privacy Patchwork

    Tennessee Joins the Fray as Legislature Passes Consumer Privacy Law

    Consumer Privacy Law Comes to Big Sky Country as Montana Passes New Law

    Indiana Passes Consumer Privacy Bill

    Iowa’s New Privacy Law: The Basics

    Colorado Finalizes Sweeping New Privacy Rules; Iowa Joins the Fray

    Preparing for New Consumer Privacy laws in Colorado, Connecticut and Utah

    Authors

    David P. Saunders

    Partner

    Chicago

    More insights

  • With New Facility Staffing Expectations, CMS Proposes Sea Change for Long-Term Care Industry

    With New Facility Staffing Expectations, CMS Proposes Sea Change for Long-Term Care Industry

    ARTICLE / CLIENT ALERT

    With New Facility Staffing Expectations, CMS Proposes Sea Change for Long-Term Care Industry

    September 13, 2023

    Read time: 10 min

    Key takeaways
    Overview

    In February 2022, US President Joseph Biden announced an overhaul of regulations affecting nursing homes. These reforms, aimed at enhancing the safety and quality of care for nursing-home residents, focus on improving transparency and accountability. The Centers for Medicare & Medicaid Services (CMS) continued this goal of reforming the senior services industry on September 6, 2023, by publishing a proposed rule to establish minimum nursing staff requirements for long-term care facilities (LTCFs) participating in Medicare and Medicaid:

    • Every LTCF must ensure that registered nurses (RNs) provide a minimum of 0.55 hours per resident day (HPRD) of direct patient services, and nurse aides (NAs) must offer 2.45 HPRD, regardless of the individual LTCF’s patient case-mix.
    • All LTCFs must also maintain an RN on site 24 hours per day, seven days per week at each Medicare- and Medicaid-certified facility.

    CMS estimates that approximately 79% of LTCFs will need to strengthen staffing in facilities to meet these requirements. To accomplish this, CMS offers a staggered rollout and an exemption process to account for the nursing shortage nationwide and the larger challenges specific to rural and underserved communities. It is possible that the Department of Health and Human Services (HHS) Health Workforce Initiative may help to mitigate some of these ongoing shortages.

    In depth

    A. Staffing Requirements

    Under current requirements to comply with Medicare and Medicaid Conditions for Coverage and Participation (CoP), LTCFs are required to employ “sufficient” and “qualified” nursing staff with appropriate competencies and skill sets to address the healthcare needs of residents in the applicable facilities, as determined by resident assessments and individual care plans. This includes providing licensed nurses and other nursing personnel on a 24-hour-per-day basis, designating a licensed nurse to serve as charge nurse for each shift and using the services of an RN for at least eight consecutive hours every day.

    With these current standards, CMS has identified ongoing safety and quality concerns for residents receiving care in Medicare- and Medicaid-certified LTCFs due to chronic understaffing. The proposed rule points to evidence demonstrating the importance of staffing to resident health and safety, showing staffing levels are closely correlated to the quality of care that a resident receives and health outcomes. CMS outlines the need for these changes in staffing expectations due to continued insufficient workforce at LTCFs, noncompliance by a subset of facilities, the need to create a consistent lower threshold for nurse-to-resident ratios across states, and to reduce the risk of residents receiving unsafe and low-quality care.
    The Biden administration’s efforts to establish consistent national minimum staffing standards in LTCFs uses a multifaceted approach, including relying on nursing home staffing studies conducted in 2001 and 2022 and through the FY 2023 Skilled Nursing Facility Prospective Payment System Proposed Rule, which sought public comments on minimum LTCF staffing standards. On April 18, 2023, President Biden issued an Executive Order on Increasing Access to High-Quality Care and Supporting Caregivers, directing the secretary of HHS to consider actions to address and reduce chronic understaffing in LTCFs. The study revealed a close correlation between staffing levels and the quality of care received by residents, with significant impacts on health outcomes.

    Using the aforementioned studies and comments as guideposts, on September 6, 2023, HHS issued proposed rules and solicited comments regarding minimum staffing standards applicable to LTCFs that participate in Medicare and Medicaid. Specifically, if finalized in their proposed form, the proposed rules will require LTCFs to have an RN on site 24 hours per day, seven days per week. Additionally, LTCFs would be required to employ a sufficient number of RNs to provide 0.55 HPRD of direct patient services and a sufficient number of NAs to ensure residents receive 2.45 hours of care from an NA per resident per day. Notably, the proposed rules do not prescribe a minimum staffing standard for licensed practical nurses (LPNs) or licensed vocational nurses (LVNs) because studies showed more positive clinical outcomes are associated with increasing the number of RNs and NAs but no association between LPNs’ and LPVs’ HPRD at any level and safe, quality care. The reliance on LPNs and LPVs varies by state, and LPNs and LPVs often operate beyond their scope of licensure when RNs are insufficiently staffed.

    B. Assessment Requirement

    The proposed rules aim to create a consistent national minimum nursing staff standard to address the wide variations in state laws. Currently, 38 states and the District of Columbia have minimum staffing standards. The proposed RN requirement of 0.55 HPRD is lower than that of only the District of Columbia, while the proposed NA requirement of 2.45 HPRD exceeds all states, including the District of Columbia. Due in part to the disparate tapestry of state laws, CMS acknowledged concerns that there may be facilities that currently exceed the proposed minimum staffing levels and that may view this proposal as an incentive to lower staffing levels to meet the new minimums. CMS emphasized that, consistent with existing regulations, facilities must continue to conduct and document a facility-wide assessment of resources needed to competently care for residents (including obligations to identify the resident demographics and any ethnic, cultural or religious factors that may affect resident care) and of the facility’s existing and needed resources, as well as a facility and community-based risk assessment. These assessments would determine if a facility must provide more nursing services than the proposed federal floor, and whether staff must have particular competencies and skill sets to provide safe and quality care to residents. Facilities must also use the assessment to establish a staffing plan to address staff turnover and to propose ways to retain necessary staff. Assessments must continue to be used to determine necessary resources required to care for residents based on resident need, regardless of whether the facility is staffed at or above the new minimum requirements. It is likely that CMS and state regulators will review facilities’ assessments as part of licensure and certification processes.

    C. Exemptions

    CMS proposes certain exemption criteria for LTCFs struggling to comply with HPRD requirements due to workforce unavailability, shortages or challenges in hiring and retaining nursing staff, contingent on health and safety assessments; however, CMS is not proposing an exemption for the obligation to have an RN on site at all times. To qualify for an exemption, an LTCF must meet the following criteria:

    • Location: The LTCF must be located in an area where the supply of nursing staff is insufficient to meet geographic area needs or is 20 miles or more from the next-closest LTCF, as determined by CMS.
    • Demonstrated good-faith effort to hire and retain staff: LTCFs must document recruitment efforts and provide wages on par with regional averages.
    • Demonstrated financial commitment: LTCFs must provide documentation of their financial resources expended annually on nurse staffing relative to revenue.

    Exemptions will not be granted to LTCFs that have failed to submit payroll-based journal system data, must not be designated as a special focus facility, and must not have been cited in the previous year for widespread insufficient staffing leading to resident harm. Exemptions, initially lasting one year, may be extended in one-year increments, with exempt facilities’ status published on the Nursing Home Care Compare website.

    D. Implementation

    The proposed minimum staffing standards will roll out in three stages over three years. The timeline below applies to facilities located in urban areas:

    • Phase 1 mandates compliance with new facility assessment requirements within 60 days of the final rule’s publication.
    • Phase 2 requires 24/7 RN availability compliance two years after publication of the final rule.
    • Phase 3 calls for compliance with the 0.55 RN HPRD and 2.45 NA HPRD requirements three years after publication of the final rule.

    Rural LTCFs will follow a slightly different timeline to allow more time to comply with staffing requirements, following the same three phases but implemented over five years:

    • Phase 1 will follow the same timeline for LTCFs in urban areas, requiring compliance with the new facility assessment within 60 days of publication of the final rule.
    • Phase 2 requires 24/7 RN availability compliance three years after publication of the final rule.
    • Phase 3 compliance with the 0.55 RN HPRD and 2.45 NA HPRD will be required five years after publication of the final rule.

    E. Impact

    The potential impact of this rule is substantial, with an estimated 79% of LTCFs needing to increase their staff levels to meet the new requirements. CMS estimates that the new proposal will cost the LTCF industry more than $40 billion over the next 10 years. Meeting these new requirements or qualifying for an exemption may prove challenging for many facilities still struggling to recover from the devastating impact that COVID-19 had on the senior-services industry. As the proposed rule observed, NA positions experience high injury rates and require heavy lifting and considerable technical and interpersonal skills. Also, the median wage for NAs is generally lower than the median wage for other entry-level positions. Attracting individuals to fill crucial NA roles may require higher wages than have historically been offered, along with other creative ideas.

    The proposed rule does not include any provision requiring Medicare to increase payment rates to providers to cover the costs of the proposed requirements. Penalties imposed by CMS for noncompliance with the proposed regulations include termination of the provider agreement, temporary management, denial of payment for all Medicare and/or Medicaid individuals by CMS, denial of payment for all new Medicare and/or Medicaid admissions, civil money penalties, state monitoring, transfer of residents, facility closure, directed plans of correction, directed in-service training, and alternative or additional state remedies approved by CMS. Penalties are based on the scope and severity of the impact on resident health and safety.

    Amidst these significant challenges and ramifications, the Biden administration is offering solutions as part of a broader effort to reform quality and safety of care in the senior-services industry, including a focus by HHS and the Health Resources and Services Administration (HRSA) on stimulating participation in nursing careers. The HHS Health Workforce Initiative proposes large financial investments for HRSA to fund workforce training, scholarships, loan repayments and well-being programs across healthcare workforce disciplines, including nursing. HRSA also recently announced awards of more than $100 million to grow the nursing workforce through funding to help LPNs and LVNs become RNs, training nurses in gaining specific knowledge in primary care, mental health care and maternal healthcare service, and providing awards to nursing schools to provide low-interest loans and loan cancellation to incentivize careers as nursing-school faculty. This follows a 2022 HRSA announcement of $13 million in grants to expand nursing education and training, as well as the Department of Labor’s Nursing Expansion Grant Program (also announced in 2022) which will provide $80 million in grants to help address bottlenecks in training the US nursing workforce and expand and diversify the pipeline of qualified nursing professionals.

    Because the proposed rule introduces an obligation for states to report the percentage of Medicaid payments allocated to compensation for direct-care workers and support staff on a facility-by-facility basis, it may become easier for consumers to select care facilities with sufficient staffing to meet residents’ needs and for government regulatory bodies to identify facilities in need of more oversight.

    CMS is seeking comments on various aspects of the proposed rule, including different staffing models, setting standards for NAs, introducing non-nurse staffing requirements and exploring alternative minimum staffing policies based on nurse type and shift requirements. The comment period ends on November 6, 2023. Because this proposed rule represents a significant change in the regulatory landscape for LTCFs, stakeholders should carefully assess the rule’s implications and investigate the next steps required to achieve compliance.

    Authors

    MaryKathryn Hurd

    Senior Knowledge Management Manager

    Washington, DC

    More insights